This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine safety and efficacy of bortezomib (PS-341) in combination with idarubicin in a phase I and II clinical trial for patients with AML. The rationale for this novel clinical trial is based on our preclinical studies demonstrating a strong tumor-specific induction of apoptosis for primary human AML cells using the combination of bortezomib and idarubicin. Elderly and relapsed AML patients have been targeted for this study due to the lack of a 'standard of care' and poor outcomes for these patients owing to a preponderance of poor-risk cytogenetics, multi-drug resistance, and antecedent co-morbidities. We expect to define dose-limiting toxicities and a maximal tolerated dose of bortezimib when combined with idarubicin in a phase I study; subsequently, safety and efficacy of the combination at the designated dose will be explored in a phase II study with expanded enrollment. We anticipate that with this regimen we will observe potent anti-leukemia activity, complete clinical remissions and less overall toxicity.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kentucky
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Reed, Rebecca G; Greenberg, Richard N; Segerstrom, Suzanne C (2017) Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade. Brain Behav Immun 61:14-20
Abshire, Demetrius A; Moser, Debra K; Clasey, Jody L et al. (2017) Body Composition and Bone Mineral Density in Patients With Heart Failure. West J Nurs Res 39:582-599
Ahmed, Zuhayer; Hafez, M A; Bari, M A et al. (2016) Pattern of anti-diabetic drugs prescribed in a tertiary care hospital of Bangladesh. Int J Basic Clin Pharmacol 5:6-12
Harrison, Jordan M; Jung, Miyeon; Lennie, Terry A et al. (2016) Refusal to participate in heart failure studies: do age and gender matter? J Clin Nurs 25:983-91
Nagarajan, Radhakrishnan; Miller, Craig S; Dawson 3rd, Dolph et al. (2015) Patient-Specific Variations in Biomarkers across Gingivitis and Periodontitis. PLoS One 10:e0136792
Ebersole, Jeffrey L; Nagarajan, Radhakrishnan; Akers, David et al. (2015) Targeted salivary biomarkers for discrimination of periodontal health and disease(s). Front Cell Infect Microbiol 5:62
Ewen, Heidi H; Chahal, Jasleen K; Fenster, Emily S (2015) A portrait of resilience in caregiving. Res Gerontol Nurs 8:29-38
Alhurani, Abdullah S; Dekker, Rebecca L; Abed, Mona A et al. (2015) The association of co-morbid symptoms of depression and anxiety with all-cause mortality and cardiac rehospitalization in patients with heart failure. Psychosomatics 56:371-80
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Janket, Sok-Ja; Baird, Alison E; Jones, Judith A et al. (2014) Number of teeth, C-reactive protein, fibrinogen and cardiovascular mortality: a 15-year follow-up study in a Finnish cohort. J Clin Periodontol 41:131-40

Showing the most recent 10 out of 232 publications